Back to top
more

Grifols (GRFS)

(Real Time Quote from BATS)

$8.78 USD

8.78
98,018

-0.02 (-0.23%)

Updated Nov 5, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

How Grifols (GRFS) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Actinium Treats First Patient in AML Study on Actimab-A Combo

by Zacks Equity Research

Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 5th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

GRFS or IONS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. IONS: Which Stock Is the Better Value Option?

Company News for Jul 8, 2019

by Zacks Equity Research

Companies In The News Are: OASM,GOL,GRFS,DELL

GRFS or ORINY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. ORINY: Which Stock Is the Better Value Option?

Grifols (GRFS) Surges: Stock Moves 5.4% Higher

by Zacks Equity Research

Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?

by Zacks Equity Research

Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

    Henry Schien to Distribute Grifols Product in United States

    by Zacks Equity Research

    We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

      Should Value Investors Consider Grifols (GRFS) Stock Now?

      by Zacks Equity Research

      Is Grifols (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

        Should Value Investors Consider Grifols (GRFS) Stock Right Now?

        by Zacks Equity Research

        Is Grifols a great pick from the value investor's perspective right now? Read on to know more.

          VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

          by Zacks Equity Research

          VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

            Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

            by Zacks Equity Research

            Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

              Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

              by Zacks Equity Research

              GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.

                Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View

                by Zacks Equity Research

                Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.

                  AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                  by Zacks Equity Research

                  AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                    Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

                    by Zacks Equity Research

                    The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

                      Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra

                      by Zacks Equity Research

                      Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra

                        GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%

                        by Zacks Equity Research

                        GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.

                          Kevin Matras headshot

                          How to Uncover Institutional Buying

                          by Kevin Matras

                          Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include ABR, CVGI, GRFS, MTCH and XCRA.

                            AMAG Files for FDA Approval of Subcutaneous Form of Makena

                            by Zacks Equity Research

                            AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

                              Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session

                              by Zacks Equity Research

                              Ohr Pharmaceutical, Inc. (OHRP) moved big last session, as its shares jumped 15% on the day.

                                Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%

                                by Zacks Equity Research

                                Infinity Pharmaceuticals, Inc. (INFI) shares rose over 19% in the last trading session.

                                  TherapeuticsMD Falls on Likely Delay in TX-004HR Approval

                                  by Zacks Equity Research

                                  Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July